The OncLive® Sponsored section encompasses all sponsored content that is presented as articles, video interviews, webinars, blog posts, and more across various types of malignancies, including breast cancer, lung cancer, hematologic cancers, gynecologic cancers, gastrointestinal cancers, genitourinary cancers, and more.
June 2nd 2020
Amgen Oncology is committed to investigating innovative approaches to fighting cancer, across both hematological malignancies and solid tumors.
May 30th 2020
On Friday 29 May at the ASCO20 Virtual Scientific Programme, Roche presented updated data from the pivotal phase III ALEX clinical study.
May 4th 2020
Continued research is critical to potentially bring a targeted therapeutic option to patients with higher-risk myelodysplastic syndromes, to improve overall survival, manage symptoms, and preserve quality of life.
September 28th 2019
Two research papers presented by Roche and Foundation Medicine at the 2019 European Society of Medical Oncology (ESMO) Annual Meeting demonstrate both the promise of an innovative precision medicine driven clinical trial for patients with cancer of unknown primary, as well as the challenges of identifying eligible patients for the trial, according to ESMO guidelines.
June 25th 2019
Angeles Alvarez Secord, MD, MHSc, discusses the importance of genetic testing and tumor testing in ovarian cancer and the potential impact on treatment decisions.
June 17th 2019
Gary Fanjiang, MD, vice president of Biosimilars Global Development, Amgen, discusses the development of biosimilars and some of the clinical considerations related to their use.
March 5th 2019
New data presented at this year’s American Society of Hematology Annual Meeting showed that adding DARZALEX® (daratumumab) to standard of care multiple myeloma therapies may extend survival and achieve levels of minimal residual disease not previously seen.
January 13th 2019
Advancing cancer care requires more than just science. It’s a collective effort driven by passionate individuals and organizations dedicated to making a difference for those living with and affected by cancer.
October 25th 2018
Investigators are optimistic that LN-145, an autologous tumor-infiltrating lymphocyte investigational therapy, could be a potential treatment option for patients with recurrent, metastatic, or persistent cervical cancer.
May 4th 2018
While there are efforts underway to address the significant unmet need for treatments at every stage of the lung cancer continuum, there has been rapid progress in NSCLC.
February 15th 2018
Lilly hosted an immersive and interactive reception during the 2018 Gastrointestinal Cancers Symposium entitled,
July 18th 2017
Since the approval of LYNPARZA, over 3,000 US women with germline BRCA-mutated advanced ovarian cancer have been treated with this important medicine.